Clinical trials: Lower Urinary Tract Symptom
- Condition Lower Urinary Tract Symptom
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Overactive Bladder, Fecal Incontinence
InterStim Micro Post Market Clinical Follow-up Study (ELITE)
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.
- Conditions
- Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
- Trial name
- ELITE (NCT04506866)
- Testing
- InterStim Micro
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 148 people
- Sponsor
- MedtronicNeuro
Urinary Bladder, Overactive
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive…
- Trial name
- NCT00613327
- Testing
- Oxybutynin chloride OROS
- Volunteers
- 345 people
- Sponsor
- Janssen Korea, Ltd., Korea
Overactive Bladder, Urinary Incontinence
A Research Study for Patients With Overactive Bladder
The purpose of this study is to investigate whether injections of botulinum toxin Type A into the bladder are safe and effective in treating overactive bladder.
- Trial name
- NCT00168454
- Testing
- botulinum toxin Type A
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 313 people
- Sponsor
- Allergan
Atrophic Vaginitis
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo.
- Trial name
- NCT02195986
- Testing
- Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream
- Where
- 21 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Urinary Incontinence
Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence Products
The purpose of this post market clinical investigation is to demonstrate the performance and safety of the TENA SmartCare Change Indicator.
- Trial name
- NCT04846270
- Testing
- TENA SmartCare Change Indicator
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Essity Hygiene and Health AB
Over-Active Bladder
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
- Trial name
- NCT01777217
- Testing
- Solifenacin succinate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Advanced Research Network
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Embosphere® PROstate Post Market Study
Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The goal of this post market study is to evaluate long-term safety and effectiveness in a 'real world' setting.
- Trial name
- PROstate (NCT03527589)
- Testing
- Prostate artery embolization
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 499 people
- Sponsor
- Merit Medical Systems, Inc.
Urinary Incontinence, Urgency-frequency, Overactive Bladder
InSite for Over Active Bladder
The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2.
- Trial name
- InSite - OAB (NCT00547378)
- Testing
- InterStim, Standard Medical Therapy
- Volunteers
- 571 people
- Sponsor
- MedtronicNeuro
Nocturia
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI…
- Trial name
- IMPACT (NCT01552343)
- Testing
- Desmopressin
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Overactive Urinary Bladder
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
The study is designed to investigate the effects of the investigational drug vibegron (MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive bladder.
- Trial name
- NCT01500382
- Testing
- Vibegron, Tolterodine ER, Prophylactic Antibiotic
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Nocturia Associated With Nocturnal Polyuria
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin…
- Trial name
- NCT00902265
- Testing
- desmopressin
- Where
- 140 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
- Trial name
- NCT01259128
- Testing
- SER120 Nasal Spray 500 ng/day, SER120 nasal spray 750 ng/day
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan
Urgency Frequency, Urinary Urge Incontinence
InterStim Therapy Programming Study
This study assessed the effect of different InterStim rate settings on voiding diary outcomes. Specifically, the study evaluated how 3 different rate settings affected the number of urinary incontinent episodes per day collected…
- Trial name
- NCT01009333
- Testing
- InterStim Therapy at rate 5.2 Hz, InterStim Therapy at rate 14 Hz, InterStim Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Stress Urinary Incontinence
Autologous Cell Therapy for Female Stress Urinary Incontinence
The Autologous Cell Therapy for Female SUI study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million Cook MyoSite Autologous Muscle Derived Cells for treatment of Stress Urinary…
- Trial name
- NCT01008943
- Testing
- Autologous Muscle Derived Cells
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Cook MyoSite
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.
- Trial name
- NCT00575016
- Testing
- botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U)
- Where
- 6 sites in Egypt, Greece and 4 more
- Volunteers
- 74 people
- Sponsor
- Allergan